Therapeutic activity of lenalidomide in mantle cell lymphoma and indolent non-hodgkins lymphomas

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  Gunnellini, Marco ^a   Falchi, Lorenzo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETOPOSIDE; INTERCELLULAR ADHESION MOLECULE 1; LENALIDOMIDE; MELPHALAN; PREDNISONE; RITUXIMAB; VASCULAR CELL ADHESION MOLECULE 1; VINCRISTINE;

ANEMIA; B CELL LYMPHOMA; CANCER SURVIVAL; CELL CYCLE ARREST; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

EID: 84863658973     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/523842     Document Type: Review

References (37)

1. Kaunshansky K., Lichtman M., Beutler E., Kipps T., Prchal J., Seligsohn U., Williams Hematology 2011 8th McGrow-Hill
2. Swerdlow S. H., Campo E., Harris N. L., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 4th WHO Press
3. van de Schans S. A., Steyerberg E. W., Nijziel M. R., Creemers G. J., Janssen-Heijnen M. L., van Spronsen D. J., Validation, revision and extension of the follicular lymphoma international prognostic index (FLIPI) in a population-based setting Annals of Oncology 2009 20 10 1697 1702
4. Geisler C. H., Kolstad A., Laurell A., Rty R., Jerkeman M., Eriksson M., Nordstrm M., Kimby E., Boesen A. M., Nilsson-Ehle H., Kuittinen O., Lauritzsen G. F., Ralfkir E., Ehinger M., Sundstrm C., Delabie J., Karjalainen-Lindsberg M. L., Brown P., Elonen E., The mantle cell lymphoma international prognostic index (MIPI) is superior to the international prognostic index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT) Blood 2010 115 8 1530 1533
5. Sehn L. H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., Klasa R., Savage K. J., Shenkier T., Sutherland J., Gascoyne R. D., Connors J. M., The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 2007 109 5 1857 1861 (Pubitemid 46348180)
6. Schulz H., Bohlius J. E., Trelle S., Skoetz N., Reiser M., Kober T., Schwarzer G., Herold M., Dreyling M., Hallek M., Engert A., Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis Journal of the National Cancer Institute 2007 99 9 706 714 (Pubitemid 47078732)
7. Sachanas S., Pangalis G. A., Vassilakopoulos T. P., Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen Leukemia Lymphoma 2011 52 3 387 393
8. Kersten M. J., Radioimmunotherapy in follicular lymphoma: some like it hot... Transfusion and Apheresis Science 2011 44 2 173 178
9. Gopal A. K., Rajendran J. G., Gooley T. A., Pagel J. M., Fisher D. R., Petersdorf S. H., Maloney D. G., Eary J. F., Appelbaum F. R., Press O. W., High-dose [ 131 I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ≥ 60 years old with relapsed or refractory B-cell lymphoma Journal of Clinical Oncology 2007 25 11 1396 1402 (Pubitemid 46706888)
10. Wiernik P. H., Lossos I. S., Tuscano J. M., Justice G., Vose J. M., Cole C. E., Lam W., McBride K., Wride K., Pietronigro D., Takeshita K., Ervin-Haynes A., Zeldis J. B., Habermann T. M., Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma Journal of Clinical Oncology 2008 26 30 4952 4957
11. Witzig T. E., Wiernik P. H., Moore T., Reeder C., Cole C., Justice G., Kaplan H., Voralia M., Pietronigro D., Takeshita K., Ervin-Haynes A., Zeldis J. B., Vose J. M., Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma Journal of Clinical Oncology 2009 27 32 5404 5409
12. Reeder C. B., Witzig T. E., Zinzani P. L., Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003) Journal of Clinical Oncology 2009 27 15, supplement, abstract e19504
13. Habermann T. M., Lossos I. S., Justice G., Vose J. M., Wiernik P. H., McBride K., Wride K., Ervin-Haynes A., Takeshita K., Pietronigro D., Zeldis J. B., Tuscano J. M., Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma British Journal of Haematology 2009 145 3 344 349
14. Witzig T. E., Vose J. M., Zinzani P. L., Reeder C. B., Buckstein R., Polikoff J. A., Bouabdallah R., Haioun C., Tilly H., Guo P., Pietronigro D., Ervin-Haynes A. L., Czuczman M. S., An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma Annals of Oncology 2011 22 7 1622 1627
15. Roussel M., Facon T., Moreau P., Harousseau J. L., Attal M., Firstline treatment and maintenance in newly diagnosed multiple myeloma patients Recent Results in Cancer Research 2011 183 189 206
16. Gentile M., Recchia A. G., Vigna E., Mazzone C., Lucia E., Gigliotti V., Bossio S., Madeo A., Morabito L., Servillo P., Franzese S., Caruso N., De Stefano L., Bisconte M. G., Gentile C., Morabito F., Lenalidomide in the treatment of chronic lymphocytic leukemia Expert Opinion on Investigational Drugs 2011 20 2 273 286
17. Dueck G., Chua N., Prasad A., Finch D., Stewart D., White D., Van Der Jagt R., Johnston J., Belch A., Reiman T., Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-hodgkin lymphoma Cancer 2010 116 19 4541 4548
18. Qian Z., Zhang L., Cai Z., Sun L., Wang H., Yi Q., Wang M., Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo Leukemia Research 2011 35 3 380 386
19. Chanan-Khan A. A., Cheson B. D., Lenalidomide for the treatment of B-cell malignancies Journal of Clinical Oncology 2008 26 9 1544 1552
20. Kotla V., Goel S., Nischal S., Heuck C., Vivek K., Das B., Verma A., Mechanism of action of lenalidomide in hematological malignancies Journal of Hematology and Oncology 2009 2, article 36
21. Reddy N., Hernandez-Ilizaliturri F. J., Deeb G., Roth M., Vaughn M., Knight J., Wallace P., Czuczman M. S., Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo British Journal of Haematology 2008 140 1 36 45 (Pubitemid 350233246)
22. Chanan-Khan A. A., Cheson B. D., Lenalidomide for the treatment of B-cell malignancies Journal of Clinical Oncology 2008 26 9 1544 1552
23. Chang D. H., Liu N., Klimek V., Hassoun H., Mazumder A., Nimer S. D., Jagannath S., Dhodapkar M. V., Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications Blood 2006 108 2 618 621 (Pubitemid 44061362)
24. Wu L., Adams M., Carter T., Chen R., Muller G., Stirling D., Schafer P., Bartlett J. B., Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells Clinical Cancer Research 2008 14 14 4650 4657
25. Zhang L., Qian Z., Cai Z., Sun L., Wang H., Bartlett J. B., Yi Q., Wang M., Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo American Journal of Hematology 2009 84 9 553 559
26. Zinzani P. L., Witzig T. E., Vose J. M., Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of an international study (NHL-003) Blood 2008 112, abstract 262
27. Wang M., Fayad L., Hagemeister F., A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy Journal of Clinical Oncology 2007 25 18, supplement, abstract 8030
28. Dutia M., DeRoock I., Chee K., R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed/ refractory indolent non-Hodgkins lymphoma (NHL) Blood 2009 114, abstract a1679
29. Zaja F., De Luca S., Vitolo U., Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neoangiogenic biomarkers Haematologica 2012 97 3 416 422
30. Morrison V. A., Jung S., Johnson J. L., A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501) Journal of Clinical Oncology 2011 29, abstract TPS223
31. Fowler N. H., McLaughlin P., Hagemeister F. B., Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma Journal of Clinical Oncology 2010 28 15, supplement, abstract a8036
32. Samaniego F., Hagemeister F., Mclaughlin P., High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria Journal of Clinical Oncology 2011 29, abstract a8030
33. Tilly H., Morschhauser F., Salles G. A., Phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas Blood 2011 118 21, abstract a1632
34. Kenkre V. P., Long W. L., Eickhoff J. C., Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the wisconsin oncology network Leukemia Lymphoma 2011 52 9 1675 1680
35. Kluin-Nelemans J. C., Hoster E., Walewski J., R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma Blood 2011 118, abstract a439
36. Jerkeman M., Kolstad A., Laurell A., Lenalidomide, bendamustine, and rituximab as first-line therapy for patients 65 years with mantle cell lymphoma: the nordic lymphoma group MCL4 (LENA-BERIT) trial Journal of Clinical Oncology 2010 28 18, supplement, abstract a18567
37. Ahmadi T., Chong E. A., Gordon A., Phase II trial of lenalidomiderituximab +/- dexamethasone in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab Blood 2011 118, abstract a266